Zimmer Biomet Holdings, Inc. - ZBH STOCK NEWS

Zimmer Biomet Holdings has launched an independent 501(c)(3) organization named Movement is Life, Inc., aimed at addressing musculoskeletal health disparities among underserved populations. Founded in 2010, Movement is Life will focus on education, early intervention, and advocacy. The Zimmer Biomet Foundation has committed multi-million dollar support for operational costs. The inaugural Board consists of notable healthcare leaders, with Millicent Gorham appointed as Executive Director, ensuring continuity of current programs and expanding partnerships to enhance the coalition's impact.

Zimmer Biomet announced the appointment of Keri P. Mattox as Chief Communications and Administration Officer, effective May 26, 2022. In her expanded role, she will oversee the company's Environmental, Social and Governance (ESG) strategy alongside enhancing CEO visibility and engagement. Mattox has been with Zimmer Biomet since January 2020, previously serving as Senior Vice President of Investor Relations and Chief Communications Officer. Her experience includes roles at W2O Group and AmerisourceBergen, reinforcing a strategic focus on integrating communications and investor relations.

Zimmer Biomet Holdings, a global leader in medical technology, announced a quarterly cash dividend of $0.24 per share for Q2 2022. This dividend is payable on or about July 29, 2022, to stockholders of record as of the close of business on June 27, 2022. The company continues to emphasize its commitment to enhancing patient mobility and health through innovative products and integrated digital technologies. With over 90 years of experience, Zimmer Biomet aims to deliver high-quality solutions worldwide.

Zimmer Biomet appointed Paul Stellato as Vice President, Controller, and Chief Accounting Officer. Stellato brings over two decades of financial experience, previously serving as Vice President of Finance at Xylem Inc. His expertise spans controllership, FP&A, investor relations, and internal audit, bolstering Zimmer Biomet's leadership team. Suky Upadhyay, CFO, expressed confidence in Stellato's ability to advance the company's financial strategies. With a strong educational background, including a Bachelor’s from Villanova University and an MBA from NYU Stern, Stellato is also a Certified Public Accountant.

Zimmer Biomet introduced new artificial intelligence capabilities in its Omni Suite, aimed at enhancing surgical workflow efficiency. This intelligent operating room solution automates manual tasks, providing real-time workflow metrics through automatic recognition of key milestones, such as patient entry and anesthesia timing. The AI feature complements the existing ZBEdge technology, enhancing patient outcomes and surgical experiences. Currently available in the United States, the Omni Suite demonstrates Zimmer Biomet's commitment to innovation in medical technology.

Zimmer Biomet Holdings, Inc. (ZBH) reported first quarter 2022 net sales of $1.663 billion, marking a 3.9% increase year-over-year. Adjusted diluted earnings per share were $1.61, while diluted earnings per share stood at $0.35.

The company raised its full-year guidance, now projecting revenue growth of (1.5)% to 0.5% and adjusted diluted EPS of $6.65 to $6.85. The spinoff of ZimVie was completed on March 1, 2022, and notable innovations such as WalkAI™ were launched, enhancing the company's digital offerings.

Zimmer Biomet Holdings (NYSE: ZBH) will present at the BofA Securities Healthcare Conference on May 11, 2022, at 5:00 p.m. Eastern Time. The presentation will feature Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. A live webcast will be available on the company's Investor Relations website and will be archived for later viewing. Zimmer Biomet is a leader in medical technology, focused on enhancing mobility and health through innovative products.

ZBH has scheduled its first-quarter earnings conference call for May 3, 2022, at 8:30 a.m. ET. A news release detailing financial results will be published at 6:30 a.m. ET on the same day. Investors can access the live audio webcast via the Investor Relations website. The conference call offers a dial-in option for participants in the U.S. and Canada. The archive of the webcast will be available post-conference. Zimmer Biomet operates in over 25 countries and sells in more than 100 countries.

Zimmer Biomet Holdings (ZBH) has launched WalkAI, an innovative AI model designed to predict patients' gait speed outcomes 90 days post-hip or knee surgery. Utilizing a proprietary algorithm and data from the ZBEdge database, WalkAI offers daily personalized predictions, helping healthcare professionals identify patients who may not follow typical recovery patterns. This model enhances patient care management through the mymobility platform and represents a significant step in Zimmer Biomet's AI strategy.